SCHEMBL4678767

SCHEMBL4678767

O=C(C=C(O)c1nc[nH]n1)c1cc(Cc2ccncc2)c(CCc2ccccc2)o1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 1/20 0.36
CYP11B1 P15538 1/20 0.36
CYP11B2 P19099 1/20 0.36
NR3C2 P08235 1/20 0.35
LTA4H P09960 1/20 0.34
ABCB1 P08183 1/20 0.34
GPR52 Q9Y2T5 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
PLA2G7 Q13093 2/20 0.33
PIM1 P11309 1/20 0.32
PIM2 Q9P1W9 1/20 0.32
RAB9A P51151 1/20 0.32
KDM4E B2RXH2 1/20 0.32
HIF1A Q16665 2/20 0.31
MAPK3 P27361 1/20 0.31
MAPK1 P28482 1/20 0.31
ALDH1A1 P00352 1/20 0.31
LMNA P02545 1/20 0.31
HPGD P15428 1/20 0.31
CDC7 O00311 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4671265 0.93 ABCB1 (0.35) CYP19A1CYP11B1CYP11B2NR3C2LTA4H
SCHEMBL4671337 0.90 LMNA (0.36) NR3C2RAB9AKDM4EMAPK1ALDH1A1
SCHEMBL4674759 0.85 NR3C2 (0.36) CYP19A1CYP11B1CYP11B2NR3C2LTA4H
SCHEMBL5899405 0.85 GPR52 (0.34) CYP19A1CYP11B1CYP11B2LTA4HABCB1
SCHEMBL4673309 0.85 CYP19A1 (0.35) CYP19A1CYP11B1CYP11B2NR3C2LTA4H
SCHEMBL4672620 0.84 SNCA (0.33) PIM1PIM2LMNA
SCHEMBL4675221 0.84 KDM4E (0.34) PIM1PIM2KDM4EALDH1A1LMNA
SCHEMBL5899383 0.84 PIM1 (0.31) CYP19A1CYP11B1CYP11B2PIM1PIM2
SCHEMBL4672722 0.83 NR3C2 (0.36) CYP19A1CYP11B1CYP11B2NR3C2LTA4H
SCHEMBL4671846 0.83 LMNA (0.35) NR3C2RAB9AKDM4EMAPK1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
CN-1335834-A Aromatic heterocyclic compounds having HIV integrase inhibitory activity SHIONOGI & CO (JP) 2002-02-13 CN disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 CYP19A1 96/4885CYP11B1 63/4885CYP11B2 129/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.